Aurinia to Participate in Jefferies London Healthcare Conference
Aurinia Pharmaceuticals (NASDAQ: AUPH) announced its participation in the upcoming Jefferies Healthcare Conference in London, scheduled for November 19-21, 2024. The company's management team will engage in one-on-one meetings with investors and participate in a fireside chat and Q&A session on Wednesday, November 20, at 12:00 PM GMT/7:00 AM EST. The session will not be webcasted.
Aurinia Pharmaceuticals (NASDAQ: AUPH) ha annunciato la sua partecipazione alla prossima Jefferies Healthcare Conference a Londra, prevista per il 19-21 novembre 2024. Il team di gestione dell'azienda parteciperà a incontri individuali con investitori e prenderà parte a una chiacchierata informale e a una sessione di domande e risposte mercoledì 20 novembre, alle 12:00 GMT/7:00 AM EST. La sessione non sarà trasmessa in diretta.
Aurinia Pharmaceuticals (NASDAQ: AUPH) anunció su participación en la próxima Jefferies Healthcare Conference en Londres, programada para el 19-21 de noviembre de 2024. El equipo de gestión de la empresa se reunirá en encuentros individuales con inversores y participará en una charla informal y una sesión de preguntas y respuestas el miércoles 20 de noviembre, a las 12:00 PM GMT/7:00 AM EST. La sesión no será transmitida en línea.
아우리니아 제약 (NASDAQ: AUPH)은 2024년 11월 19일부터 21일까지 런던에서 열리는 제퍼리즈 헬스케어 컨퍼런스에 참여할 것이라고 발표했습니다. 회사의 경영진은 투자자와의 일대일 미팅에 참여하고 11월 20일 수요일 정오 12:00 PM GMT/ 오전 7:00 EST에 불쑥 대화 및 질의응답 세션에 참여할 예정입니다. 해당 세션은 웹캐스트되지 않습니다.
Aurinia Pharmaceuticals (NASDAQ: AUPH) a annoncé sa participation à la prochaine Jefferies Healthcare Conference à Londres, prévue du 19 au 21 novembre 2024. L'équipe de direction de l'entreprise participera à des réunions en tête-à-tête avec des investisseurs et animera une discussion informelle ainsi qu'une session de questions-réponses le mercredi 20 novembre, à 12h00 GMT/7h00 EST. Cette session ne sera pas diffusée en direct.
Aurinia Pharmaceuticals (NASDAQ: AUPH) gab bekannt, dass es an der bevorstehenden Jefferies Healthcare Conference in London teilnehmen wird, die für den 19. bis 21. November 2024 geplant ist. Das Management-Team des Unternehmens wird in Einzelgesprächen mit Investoren interagieren und am Mittwoch, den 20. November, um 12:00 Uhr GMT/7:00 Uhr EST an einem Kaminabend und einer Frage-und-Antwort-Runde teilnehmen. Die Sitzung wird nicht als Webcast übertragen.
- None.
- None.
Aurinia management will host one-on-one meetings with investors and will participate in a fireside chat and Q&A session on Wednesday, November 20, at 12:00 PM GMT/7:00 AM EST. This session will not include a webcast.
About Aurinia
Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Company introduced LUPKYNIS® (voclosporin), the first FDA-approved oral therapy dedicated to the treatment of adult patients with active lupus nephritis. Aurinia is also developing AUR200, a differentiated, potential best-in-class therapy for autoimmune diseases that targets both BAFF (B-cell Activating Factor) and APRIL (A Proliferation-Inducing Ligand).
View source version on businesswire.com: https://www.businesswire.com/news/home/20241114401812/en/
Media & Investor Inquiries:
Andrea Christopher
Corporate Communications & Investor Relations
Aurinia Pharmaceuticals Inc.
achristopher@auriniapharma.com
General Investor Inquiries:
ir@auriniapharma.com
Source: Aurinia Pharmaceuticals Inc.
FAQ
When is Aurinia (AUPH) presenting at the Jefferies Healthcare Conference 2024?
Will Aurinia's (AUPH) Jefferies Healthcare Conference session be webcasted?
What activities will Aurinia (AUPH) participate in at the 2024 Jefferies Healthcare Conference?
Where is the Jefferies Healthcare Conference 2024 that Aurinia (AUPH) is attending?
